Last reviewed · How we verify

salbutamol + ipratropium bromide nebules

Imperial College London · FDA-approved active Small molecule

salbutamol + ipratropium bromide nebules is a Combination bronchodilator (beta-2 agonist + anticholinergic) Small molecule drug developed by Imperial College London. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD), Acute bronchospasm in obstructive airway disease. Also known as: albuterol, Ventolin, Atrovent, Albuterol.

Salbutamol and ipratropium bromide work together as a combination bronchodilator—salbutamol activates beta-2 adrenergic receptors to relax airway smooth muscle, while ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction.

Salbutamol and ipratropium bromide work together as a combination bronchodilator—salbutamol activates beta-2 adrenergic receptors to relax airway smooth muscle, while ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction. Used for Chronic obstructive pulmonary disease (COPD), Acute bronchospasm in obstructive airway disease.

At a glance

Generic namesalbutamol + ipratropium bromide nebules
Also known asalbuterol, Ventolin, Atrovent, Albuterol
SponsorImperial College London
Drug classCombination bronchodilator (beta-2 agonist + anticholinergic)
TargetBeta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Salbutamol is a short-acting beta-2 agonist that increases intracellular cAMP, causing rapid airway smooth muscle relaxation. Ipratropium is an anticholinergic agent that blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced constriction. Together, they provide complementary bronchodilation through different pathways, resulting in improved airflow and symptom relief in obstructive airway diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about salbutamol + ipratropium bromide nebules

What is salbutamol + ipratropium bromide nebules?

salbutamol + ipratropium bromide nebules is a Combination bronchodilator (beta-2 agonist + anticholinergic) drug developed by Imperial College London, indicated for Chronic obstructive pulmonary disease (COPD), Acute bronchospasm in obstructive airway disease.

How does salbutamol + ipratropium bromide nebules work?

Salbutamol and ipratropium bromide work together as a combination bronchodilator—salbutamol activates beta-2 adrenergic receptors to relax airway smooth muscle, while ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction.

What is salbutamol + ipratropium bromide nebules used for?

salbutamol + ipratropium bromide nebules is indicated for Chronic obstructive pulmonary disease (COPD), Acute bronchospasm in obstructive airway disease.

Who makes salbutamol + ipratropium bromide nebules?

salbutamol + ipratropium bromide nebules is developed and marketed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

Is salbutamol + ipratropium bromide nebules also known as anything else?

salbutamol + ipratropium bromide nebules is also known as albuterol, Ventolin, Atrovent, Albuterol.

What drug class is salbutamol + ipratropium bromide nebules in?

salbutamol + ipratropium bromide nebules belongs to the Combination bronchodilator (beta-2 agonist + anticholinergic) class. See all Combination bronchodilator (beta-2 agonist + anticholinergic) drugs at /class/combination-bronchodilator-beta-2-agonist-anticholinergic.

What development phase is salbutamol + ipratropium bromide nebules in?

salbutamol + ipratropium bromide nebules is FDA-approved (marketed).

What are the side effects of salbutamol + ipratropium bromide nebules?

Common side effects of salbutamol + ipratropium bromide nebules include Tremor, Headache, Palpitations, Dry mouth, Nervousness, Tachycardia.

What does salbutamol + ipratropium bromide nebules target?

salbutamol + ipratropium bromide nebules targets Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium) and is a Combination bronchodilator (beta-2 agonist + anticholinergic).

Related